Xiaoyun Shang

New Capabilities

Leading MT027 across two FDA Phase 2 programs

The FDA cleared T-MAXIMUM's off-the-shelf CAR-T, MT027, for a Phase 2 trial in brain metastases from lung and breast cancer. It's the second Phase 2 clearance for the therapy, which targets the tumor protein B7-H3 and is delivered directly into the brain.

Updated Oct 13